

**Louisiana Medicaid  
Immune Globulin (Human) Criteria**

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for the use of immune globulin (human) agents.

Additional Point-of-Sale edits may apply.

**Approval Criteria for All Diagnoses**

- The requested medication is being used for a medically accepted indication as defined using the following sources [Source(s) are **stated on the request**]:
  - Food and Drug Administration (FDA); **OR**
  - Micromedex; **OR**
  - American Hospital Formulary Service (AHFS); **OR**
  - Drug-specific prescribing information (PI); **OR**
  - Disease state specific standard of care guidelines; **AND**
- The recipient is within the age parameters defined by the drug-specific prescribing information; **AND**
- The diagnosis for which the medication is requested has been confirmed by a specialist; **AND**
- The recipient has tried and failed, or has a documented medical reason for not using, all other standard of care therapies as defined per recognized guidelines; **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested medication and will not be receiving the requested medication in combination with any other medication that is contraindicated or not recommended per FDA labeling.

---

**Additional diagnosis-specific criteria**

**Primary immunodeficiency\***

- By submitting the authorization request, the prescriber attests to the following:
  - The recipient's IgG level is below normal level for indication; **AND**
  - The recipient has clinically significant deficiency of humoral immunity as evidenced by **ONE** of the following:
    - Inability to produce an adequate immunologic response to specific antigens; **OR**
    - History of recurrent infections despite prophylactic antibiotics; **AND**

- The requested dose is consistent with FDA approved package labeling, nationally recognized compendia, or peer-reviewed literature.

\* Primary Immunodeficiency includes the following: Congenital agammaglobulinemia; Hypogammaglobulinemia (Common Variable Immunodeficiency, CVID); Severe combined immunodeficiency (SCID); Wiskott-Aldrich syndrome; X-linked agammaglobulinemia or Bruton's agammaglobulinemia; Hypergammaglobulinemia; X-linked Hyper IgM syndrome.

**Duration of approval: 6 months**

---

#### **Idiopathic Thrombocytopenic Purpura (acute or chronic)**

- By submitting the authorization request, the prescriber attests that **ONE** of the following is true:
  - For recipients with a diagnosis of acute idiopathic thrombocytopenic purpura:
    - The recipient's condition is acute (defined as active bleeding, urgent invasive procedure, to defer splenectomy, platelet counts < 20,000/ul at risk for intra-cerebral hemorrhage or has life threatening bleeding); **AND**
    - The requested dose does not exceed 1g/kg daily for up to 2 days, or 400mg/kg daily for 5 days; **OR**
  - For recipients with a diagnosis of chronic idiopathic thrombocytopenic purpura:
    - The duration of illness is greater than 6 months (definition of chronic idiopathic thrombocytopenic purpura); **AND**
    - The recipient has a documented trial and failure of corticosteroids and splenectomy; **OR**
    - The recipient has a documented medical reason why they are not able to use corticosteroids; **OR**
    - The recipient is at high risk for post-splenectomy sepsis; **AND**
    - The requested dose does not exceed 1g/kg daily for up to 2 days, or 400mg/kg daily for 5 days.

**Duration of approval: Up to 5 days**

---

#### **Kawasaki Disease**

- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The requested agent is being given with high dose aspirin; **AND**
  - The requested dose does not exceed a single 2g/kg dose or a dose of 400mg/kg for five consecutive days.

**Duration of approval: Up to 5 days**

---

### **Chronic B-cell Lymphocytic Leukemia**

- The recipient's IgG level is < 500mg/dL and this is **stated on the request; AND**
- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The recipient has history of severe bacterial infections; **AND**
  - The requested dose does not exceed 400mg/kg every 3-4 weeks.

**Duration of approval: 3 months**

---

### **Bone Marrow Transplantation**

- The recipient IgG level is <400mg/dL and this is **stated on the request; AND**
- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The recipient has had a bone marrow transplant within the last 100 days; **AND**
  - The requested dose does not exceed 500mg/kg/wk for the first 100 days post-transplant.

**Duration of approval: 3 months**

---

### **Pediatric HIV**

- The recipient has a diagnosis of HIV and this is **stated on the request; AND**
- The recipient is < 13 years of age; **AND**
- The recipient's IgG level is **stated on the request; AND**
- By submitting the request, the prescriber attests to the following:
  - If the recipient's IgG level is  $\geq 400$  mg/dL, there is significant deficiency of humoral immunity as evidenced by **ONE** of the following:
    - An inability to produce an adequate immunologic response to specific antigens;  
**OR**
    - A history of recurrent bacterial infections despite prophylactic antibiotics; **AND**
  - The requested dose does not exceed 400mg/kg/dose every 14 days

**Duration of approval: 3 months**

---

### **Multifocal motor neuropathy (MMN)**

- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The duration of symptoms has been at least one month with disability; **AND**
  - Nerve conduction studies were completed to rule out other possible conditions, and confirms the diagnosis of MMN; **AND**
  - The requested dose does not exceed 2g/kg/month.

**Duration of approval: 3 months**

---

### **Chronic inflammatory demyelinating polyneuropathy (CIDP)**

- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The duration of symptoms has been at least 2 months with disability; **AND**
  - Nerve conduction studies or a nerve biopsy were completed in order to rule out other possible conditions, and confirms the diagnosis of CIDP; **AND**
  - **ONE** of the following:
    - The recipient has tried and failed, or has a medical reason for not using, corticosteroids; **OR**
    - The recipient has severe and fulminant CIDP; **AND**
  - The requested dose is consistent with FDA approved package labeling, nationally recognized compendia, or peer-reviewed literature

**Duration of approval: 3 months**

---

### **Guillain-Barre syndrome**

- By submitting the authorization request, the prescriber attests that the following statements are true:
  - The recipient has severe disease with the inability to walk without aid; **AND**
  - The onset of symptoms has occurred within the last 4 weeks; **AND**
  - The requested dose does not exceed 2g/kg/month.

**Duration of approval: 3 months**

*If criteria is met, the request will be approved for the duration listed above. If the criteria is not met, the request is referred to a clinical reviewer for medical necessity review. The clinical reviewer may override criteria when, in his/her professional judgement, the requested item is medically necessary.*

### **References**

AHFS drug information essentials. Bethesda, MD: American Society of Health-System Pharmacists. Available at [www.ahfsdruginformation.com](http://www.ahfsdruginformation.com)

Asceniv (immune globulin – human) [package insert]. Boca Raton, FL: ADMA Biologics; April 2019. <https://d1io3yog0oux5.cloudfront.net/asceniv/files/pages/full-prescribing-information/ASCENIV+PI.pdf>

Bivigam (immune globulin – human) [package insert]. Boca Raton, FL: ADMA Biologics; July 2019. <https://d1io3yog0oux5.cloudfront.net/77a9602c4556a801d7329febd9ff1058/bivigam/files/documents/prescribing-info.pdf>

CDC. Revised surveillance case definition for HIV infection – United States, 2014. MMWR 2014;63 (RR03); 1-10

Cutaquig (immune globulin – human-hipp) [package insert]. Hoboken, NJ: Octapharma USA, Inc; November 2019. [https://www.cutaquigus.com/wp-content/uploads/2020/01/pil\\_810\\_USA\\_07.pdf](https://www.cutaquigus.com/wp-content/uploads/2020/01/pil_810_USA_07.pdf)

Cuvitru (immune globulin – human) [package insert]. Lexington, MA: Baxalta US Inc; May 2019. [https://www.shirecontent.com/PI/PDFS/Cuvitru\\_USA\\_ENG.PDF](https://www.shirecontent.com/PI/PDFS/Cuvitru_USA_ENG.PDF)

Flebogamma DIF (immune globulin – human) [package insert]. Barcelona, Spain: Grifols USA; September 2019. [file:///C:/Users/Melissa%20Dear/Downloads/20191120\\_2cf22c72-64ac-45be-b7c6-d20340730096%20\(1\).pdf](file:///C:/Users/Melissa%20Dear/Downloads/20191120_2cf22c72-64ac-45be-b7c6-d20340730096%20(1).pdf)

GamaSTAN (immune globulin – human) [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=561f48de-2697-4a35-8233-bd1cdb73438f&type=display>

GamaSTAN S/D (immune globulin – human) [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; 2013. <https://www.fda.gov/media/86789/download>

Gammagard (immune globulin – human) [package insert]. Westlake Village, CA: Baxalta US Inc; June 2106. [https://www.shirecontent.com/pi/pdfs/gamliquid\\_usa\\_eng.pdf](https://www.shirecontent.com/pi/pdfs/gamliquid_usa_eng.pdf)

Gammagard S/D (immune globulin – human – solvent detergent treated) [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; October 2008. [https://www.baxter.com.pr/downloads/healthcare\\_professionals/products/GGSD\\_PI.pdf](https://www.baxter.com.pr/downloads/healthcare_professionals/products/GGSD_PI.pdf)

Gammaked (immune globulin – human) [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; June 2018. [https://www.gammaked.com/clientuploads/GAMMAKED\\_Web-Fax\\_3052575-3052576\\_21686.pdf?t=1562867757](https://www.gammaked.com/clientuploads/GAMMAKED_Web-Fax_3052575-3052576_21686.pdf?t=1562867757)

Gammaplex (immune globulin – human) [package insert]. Durham, NC: BPL, Inc; September 2019. [https://www.gammaplex.com/download/Gammaplex\\_10pct\\_US\\_PI\\_2020\\_pages.pdf](https://www.gammaplex.com/download/Gammaplex_10pct_US_PI_2020_pages.pdf)

Gamunex-C (immune globulin – human) [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020. <https://www.gamunex-c.com/documents/27482625/27482925/Gamunex-C+Prescribing+Information.pdf/9258bd0f-4205-47e1-ab80-540304c1ff8e>

Hizentra (immune globulin – human) [package insert]. Kankakee, IL: CSL Behring LLC; March 2020. <https://labeling.cslbehring.com/PI/US/Hizentra/EN/Hizentra-Prescribing-Information.pdf>

HyQvia (immune globulin – human with recombinant) [package insert]. Lexington, MA: Baxalta US Inc; February 2020. [https://www.shirecontent.com/PI/PDFS/HYQVIA\\_USA\\_ENG.pdf](https://www.shirecontent.com/PI/PDFS/HYQVIA_USA_ENG.pdf)

Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. (2020) Available at:  
<http://www.micromedexsolutions.com>

Octagam (immune globulin – human) [package insert]. Hoboken, NJ: Octapharma USA Inc.; August 2018.  
<http://labeling.pfizer.com/ShowLabeling.aspx?id=11357>

Panzyga (immune globulin – human-ifas) [package insert]. New York, NY: Pfizer labs; August 2019.  
<http://labeling.pfizer.com/ShowLabeling.aspx?id=12355>

Privigen (immune globulin – human) [package insert]. Kankakee, IL: CSL Behring LLC; March 2019.  
<http://cslbehring.vo.llnwd.net/o33/u/central/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf>

UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. (2020) Available at <https://www.uptodate.com/>

U.S. Food and Drug Administration. Center for Drug Evaluation and Research. (2020) Available at  
[www.fda.gov](http://www.fda.gov)

Xembify (immune globulin – human-klhw) [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; July 2019. <https://www.xembify.com/documents/90180901/0/Xembify+Prescribing+Information+-+2019+---+3054808/9ff0e9a4-1249-4cd7-8b10-3ce50a8fad5d>

<b>Revision</b>	<b>Date</b>
Policy created	September 2020